Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.

J Med Chem. 2019 Sep 12;62(17):8364. doi: 10.1021/acs.jmedchem.9b01259. Epub 2019 Aug 19. No abstract available.

PMID:
31424209
2.

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R, Pellegrinelli A, Testi A, Pietrantonio F, Fucà G, Wei G, Murphy D, Siena S, Isacchi A, De Braud F.

Oncotarget. 2017 Jul 24;8(33):55353-55360. doi: 10.18632/oncotarget.19512. eCollection 2017 Aug 15.

3.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

4.

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.

J Med Chem. 2016 Apr 14;59(7):3392-408. doi: 10.1021/acs.jmedchem.6b00064. Epub 2016 Mar 30. Erratum in: J Med Chem. 2019 Sep 12;62(17):8364.

PMID:
27003761
5.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.

Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.

6.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S.

Br J Cancer. 2015 Dec 22;113(12):1730-4. doi: 10.1038/bjc.2015.401. Epub 2015 Dec 3.

7.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.

Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.

J Natl Cancer Inst. 2015 Nov 12;108(1). pii: djv306. doi: 10.1093/jnci/djv306. Print 2016 Jan.

8.

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A.

Mol Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001. Epub 2014 Jun 12.

9.

Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.

Casuscelli F, Ardini E, Avanzi N, Casale E, Cervi G, D'Anello M, Donati D, Faiardi D, Ferguson RD, Fogliatto G, Galvani A, Marsiglio A, Mirizzi DG, Montemartini M, Orrenius C, Papeo G, Piutti C, Salom B, Felder ER.

Bioorg Med Chem. 2013 Dec 1;21(23):7364-80. doi: 10.1016/j.bmc.2013.09.054. Epub 2013 Oct 2.

PMID:
24139169
10.

RET inhibition: implications in cancer therapy.

Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA.

Expert Opin Ther Targets. 2013 Apr;17(4):403-19. doi: 10.1517/14728222.2013.758715. Epub 2013 Mar 6. Review.

PMID:
23461584
11.

ALK Inhibitors, a Pharmaceutical Perspective.

Ardini E, Galvani A.

Front Oncol. 2012 Feb 22;2:17. doi: 10.3389/fonc.2012.00017. eCollection 2012.

12.

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M.

Cancer Lett. 2010 Dec 28;299(2):81-94. doi: 10.1016/j.canlet.2010.09.001. Epub 2010 Oct 8. Review.

PMID:
20934803
13.

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.

Bossi RT, Saccardo MB, Ardini E, Menichincheri M, Rusconi L, Magnaghi P, Orsini P, Avanzi N, Borgia AL, Nesi M, Bandiera T, Fogliatto G, Bertrand JA.

Biochemistry. 2010 Aug 17;49(32):6813-25. doi: 10.1021/bi1005514.

PMID:
20695522
14.

Through the "gatekeeper door": exploiting the active kinase conformation.

Zuccotto F, Ardini E, Casale E, Angiolini M.

J Med Chem. 2010 Apr 8;53(7):2681-94. doi: 10.1021/jm901443h. Review. No abstract available.

PMID:
20000735
15.

Reliable high-throughput functional screening with 3-FABS.

Dalvit C, Ardini E, Fogliatto GP, Mongelli N, Veronesi M.

Drug Discov Today. 2004 Jul 15;9(14):595-602. Review.

PMID:
15239978
16.

A general NMR method for rapid, efficient, and reliable biochemical screening.

Dalvit C, Ardini E, Flocco M, Fogliatto GP, Mongelli N, Veronesi M.

J Am Chem Soc. 2003 Nov 26;125(47):14620-5.

PMID:
14624613
17.
18.

p53-dependent downregulation of metastasis-associated laminin receptor.

Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De Bortoli M, Castronovo V, Ménard S.

Oncogene. 2002 Oct 24;21(49):7478-87.

19.

Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments.

Ardini E, Sporchia B, Pollegioni L, Modugno M, Ghirelli C, Castiglioni F, Tagliabue E, Ménard S.

Cancer Res. 2002 Mar 1;62(5):1321-5.

20.

Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.

Ardini E, Agresti R, Tagliabue E, Greco M, Aiello P, Yang LT, Ménard S, Sap J.

Oncogene. 2000 Oct 12;19(43):4979-87.

21.

The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution.

Ardini E, Pesole G, Tagliabue E, Magnifico A, Castronovo V, Sobel ME, Colnaghi MI, Ménard S.

Mol Biol Evol. 1998 Aug;15(8):1017-25.

PMID:
9718729
22.

Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.

Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S.

Oncogene. 1998 Jul 30;17(4):425-32.

23.

Formation of the 67-kDa laminin receptor by acylation of the precursor.

Butò S, Tagliabue E, Ardini E, Magnifico A, Ghirelli C, van den Brûle F, Castronovo V, Colnaghi MI, Sobel ME, Ménard S.

J Cell Biochem. 1998 Jun 1;69(3):244-51.

PMID:
9581863
24.

Heregulin beta1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein.

Magnifico A, Tagliabue E, Ardini E, Casalini P, Colnaghi MI, Ménard S.

FEBS Lett. 1998 Jan 30;422(2):129-31.

25.

A cell and mechanism-based approach for the selection of EGF receptor inhibitors.

Lanzi C, Pensa T, Cassinis M, Corti C, Gambetta RA, Pratesi G, Menta E, Ardini E, Zunino F.

Anticancer Drug Des. 1997 Sep;12(6):515-24. No abstract available.

PMID:
9311559
26.

Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin.

Ardini E, Tagliabue E, Magnifico A, Butò S, Castronovo V, Colnaghi MI, Ménard S.

J Biol Chem. 1997 Jan 24;272(4):2342-5.

27.

Production and characterization of monoclonal antibodies directed against the laminin receptor precursor.

Butò S, Ghirelli C, Aiello P, Tagliabue E, Ardini E, Magnifico A, Montuori N, Sobel ME, Colnaghi MI, Ménard S.

Int J Biol Markers. 1997 Jan-Mar;12(1):1-5.

PMID:
9176710
28.

Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells.

Magnifico A, Tagliabue E, Butó S, Ardini E, Castronovo V, Colnaghi MI, Ménard S.

J Biol Chem. 1996 Dec 6;271(49):31179-84.

29.

Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells.

Tagliabue E, Ardini E, Pellegrini R, Campiglio M, Bufalino R, Jeschke M, Groner B, Colnaghi MI, Ménard S.

Br J Cancer. 1996 Nov;74(9):1427-33.

30.

Shedding of the 67-kD laminin receptor by human cancer cells.

Karpatová M, Tagliabue E, Castronovo V, Magnifico A, Ardini E, Morelli D, Belotti D, Colnaghi MI, Ménard S.

J Cell Biochem. 1996 Feb;60(2):226-34.

PMID:
8655633

Supplemental Content

Loading ...
Support Center